Expert Opinion on Drug Safety, Volume 23, Issue 6 (2024)

Browse this journal

Expert Opinion on Drug Safety, Volume 23, Issue 6 (2024)

See all volumes and issues
Volume 23, 2024 Vol 22, 2023 Vol 21, 2022 Vol 20, 2021 Vol 19, 2020 Vol 18, 2019 Vol 17, 2018 Vol 16, 2017 Vol 15, 2016 Vol 14, 2015 Vol 13, 2014 Vol 12, 2013 Vol 11, 2012 Vol 10, 2011 Vol 9, 2010 Vol 8, 2009 Vol 7, 2008 Vol 6, 2007 Vol 5, 2006 Vol 4, 2005 Vol 3, 2004 Vol 2, 2003 Vol 1, 2002
Download citations Download PDFs Download issue

Editorial

Editorial
Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice
Jae Hui Kim
Pages: 659-661
Published online: 06 May 2024
First Page PreviewforIntraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice | Full Text | References | PDF (137.4 KB) | EPUB
  • 105 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Editorial
The cardiovascular safety of sodium nitroprusside in acute heart failure
Pier Paolo Bocchino, Filippo Angelini, Guglielmo Gallone, Simone Frea & Gaetano Maria De Ferrari
Pages: 663-666
Published online: 29 Apr 2024
First Page PreviewforThe cardiovascular safety of sodium nitroprusside in acute heart failure | Full Text | References | PDF (394.8 KB) | EPUB
  • 366 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Drug Safety Evaluation

Review Article
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation
Kazumasa Yamamoto, Shun Yamamoto & Ken Kato
Pages: 667-675
Published online: 01 May 2024
AbstractforPembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation | Full Text | References | PDF (282.4 KB) | EPUB
  • 48 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero & Matteo Megna
Pages: 677-685
Published online: 06 May 2024
AbstractforEfficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation | Full Text | References | PDF (288.9 KB) | EPUB
  • 52 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Review Article
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis
Rouhin Sen, Maria Riofrio & Jasvinder A. Singh
Pages: 687-714
Published online: 23 May 2024
AbstractforA narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis | Full Text | References | PDF (525.4 KB) | EPUB | Supplemental
  • 63 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective
Wolfgang Strube, Elias Wagner, Jurjen J. Luykx & Alkomiet Hasan
Pages: 715-729
Published online: 06 May 2024
AbstractforA review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective | Full Text | References | PDF (389.8 KB) | EPUB
  • 98 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Research

Article
Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials
Asif Muhammed, Christy Thomas, Vivekanandan Kalaiselvan & Krishna Undela
Pages: 731-742
Published online: 11 Dec 2023
AbstractforRisk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials | Full Text | References | PDF (2.4 MB) | EPUB | Supplemental
  • 295 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)
Stylianos Kandarakis, Alexandros P. Papadopoulos, Georgios Roussopoulos, Eustathios Georgopoulos, Youngsik Chung, Leonidas Doumazos, Areum Baek, Nefeli Ioanna Paizi, Hyunik Shin & Pantelis A. Papadopoulos
Pages: 743-754
Published online: 06 Sep 2023
AbstractforCOMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) | Full Text | References | PDF (586.1 KB) | EPUB | Supplemental
  • 89 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus
Ruifeng Chen, Hu Li, Wuyang Zhu, Hongbin Cheng, Yu Li, Xiaomei Li, Faliang Li, Xiaoqiang Liu, Shixiong Hu, Baigang Yan, Yishan Zheng, Yongbo Zuo, Guanmu Dong & Xiangming Li
Pages: 755-762
Published online: 12 Jul 2023
AbstractforExpert consensus on the clinical application of ormutivimab injection for use against the rabies virus | Full Text | References | PDF (1.1 MB) | EPUB
  • 1464 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article
Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system
Zhiping Li, Wenbin Zou, Jiao Yuan, Yunxiang Zhong & Zhiwen Fu
Pages: 763-770
Published online: 31 Jul 2023
AbstractforGender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system | Full Text | References | PDF (645.6 KB) | EPUB | Supplemental
  • 129 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data
Yu Yan, Ling Wang, Yanling Yuan, Jiayue Xu, Yuxian Chen & Bin Wu
Pages: 771-776
Published online: 30 Aug 2023
AbstractforA pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data | Full Text | References | PDF (285.4 KB) | EPUB | Supplemental
  • 149 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system
Chunlei Li, Zhengjun Li, Qing Sun, Yanxiao Xiang & Anchang Liu
Pages: 777-784
Published online: 25 Aug 2023
AbstractforSevere cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system | Full Text | References | PDF (257.7 KB) | EPUB | Supplemental
  • 163 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system
Lei Zhang, Chen Pan, Xinyu Yang, Dechun Jiang & Mingnan Cao
Pages: 785-792
Published online: 26 May 2023
AbstractforSodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system | Full Text | References | PDF (2.7 MB) | EPUB | Supplemental
  • 126 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles